Replies to post #512005 on NorthWest Biotherapeutics Inc (NWBO)

[hoffmann6383]

LOL, docs disagree

[Dr Bala]

Totally nonsensical fabrications.

[biosectinvestor]

No one credible accuses anyone of manipulated data with regard to this trial.

Your accusing UCLA and Kings College and numerous other top research institutions and researchers of fraud is noted, but far more likely that anonymous posters on the internet would be the fraudsters trying to convince people that such researchers and research institutions are all coordinating a fraud with regard to this trial, which they are also seeking to publish after peer review.

Quite a ridiculous notion.

[KIPK]

LOL... SMH...

VERY LONG NWBO

[HappyLibrarian]

DCVax-L is manifestly safe so our chance of failure is now logically less than that 40% you cited and that is not taking into account TLD.

[martyDg]

I’ll take 60% chance of approval that’s high imo

[Roman516]

NWBO pressing onward and forward.

However bogus information
"The failure rate of Phase 3 trial for approvals is ~40%. The primary reason:
"The reasons for these failures appear to be unchanged: 75 to 80% are due to problems with efficacy and/or safety."

NWBO's questionable manipulated trial data, complete confounding of the naive OS, post hoc data dredged recurrent OS arm (n=64) -- Good luck boys."

The OS data results exceed expectations, the majority of the doctors, scientist, and professionals all agree that DCVax-L will be able to help many cancer patients and the results are proving this. NWBO is like back to the future where the flux capacitor helmet was tossed away. NWBO's OS results will pave the way to more effective cures as time moves forward.

[CherryTree1]

Repeatedly reposting a totally false post over and over even when indisputable evidence to the contrary has been provide from multiple sources does not make it true.

NWBO's questionable manipulated trial data, complete confounding of the naive OS, post hoc data dredged recurrent OS arm (n=64) -- Good luck boys.

Again from Oct 5 2020 press release announcing data lock:
The statisticians will proceed as quickly as possible with analyses of the raw data and prepare summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, who will analyze the data with the statisticians in preparation for public announcement and scientific publication.
All these organization and people ( the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts, ) are put in place to prevent trial data manipulation. They could not proceed without the statistical analysis without the final SAP and they would not remain silent if anything heinous was going on.